From the Journals

Trial Looks at Early Use of Mycophenolate to Reduce Flares, Nephritis


 

FROM JAMA NETWORK OPEN

How Much Might Cost Factor Into Treatment Decisions?

The study did not examine cost. Prednisone and hydroxychloroquine sulfate are inexpensive, but Dr. James said MMF can cost about $450 a month at the study dosage. However, “the average hospitalization without an ICU [intensive care unit] visit for an SLE patient is about $15,000-$20,000. If you can avoid one hospitalization, you can pay for nearly 4 years of MMF. More importantly, from a financial perspective, if you can convert a severe lupus patient to a mild/moderate lupus patient, then the annual costs of lupus decrease nearly by half, from about $52,000 per year to $25,000 per year.”

The study authors noted various limitations such as the small number of subjects, the need for a longer trial “to determine the advantages and disadvantages of early application of MMF,” and the fact that all subjects were Asian. The authors also called for confirmation via a double-blind, placebo-controlled study.

The study was funded by grants to the authors by the National Natural Science Foundation of China, Shanghai Rising-Star Program, Natural Science Foundation of Shanghai, Five-Year National Key R&D Program, and Ruijin–Zhongmei Huadong Lupus Funding. The authors had no disclosures. Dr. Costenbader disclosed consulting/research collaboration relationships with AstraZeneca, Amgen, Biogen, Bristol-Myers Squibb, GSK, Merck, Gilead, and Cabaletta. Dr. James and Dr. Wallace had no disclosures.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Air Pollution and Genetics May Raise Risk for Lupus
MDedge Dermatology
Psychiatric, Autoimmune Comorbidities Increased in Patients with Alopecia Areata
MDedge Dermatology
When Does Different Types of Organ Damage From Lupus Occur? Long-Term Study Sheds Light
MDedge Dermatology
Fillers, Hyaluronidase Relieve Orofacial Changes in Patients with Scleroderma
MDedge Dermatology
Patients With Immune-Mediated Inflammatory Diseases, Type 2 Diabetes Reap GLP-1 Receptor Agonist Benefits, Too
MDedge Dermatology
Systemic Sclerosis Without Scleroderma Has Unique Severity, Prognosis
MDedge Dermatology
What’s Causing Raynaud Phenomenon Severity to Rise With High Temperatures?
MDedge Dermatology
Current Hydroxychloroquine Use in Lupus May Provide Protection Against Cardiovascular Events
MDedge Dermatology
Belimumab Hits Newer Remission, Low Disease Activity Metrics
MDedge Dermatology
Hypnosis May Offer Relief During Sharp Debridement of Skin Ulcers
MDedge Dermatology